AMPI-109 tagged posts

Lambert, Lucia and Gari (left to right) unpack the mechanism of investigational drug, AMPI-109, to show how its inactivation of PRL-3 flips an important switch on triple-negative breast cancer.

A new study offers compelling evidence that enzyme PRL-3 is ‘switch’ in TNF-R1 pathway, determining whether pathway helps cancer cells survive or die when challenged with immunotherapy. Previous studies at the University of Colorado Cancer Center show that the experimental drug AMPI-109 potently kills triple-negative breast cancer cells. But even the most compelling evidence of cell death in a dish isn’t enough to push a drug into human clinical trials, even for triple-negative breast cancer, which has a high mortality rate and remains largely without targeted treatment options...